Blood cancer drugs
These companies develop or sell drugs and cell therapies that treat leukemia, lymphoma, myeloma and other blood cancers.
+26.3%
over 1 year · S&P 500 +11.6%
Key indicators
Health
49 / 100
Fragile
Solid
Price
P/E 27
Cheap
Expensive
Up over 1 year
11 of 20
Volatility
71%
Calm
Choppy
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 21 companies
BMY
+35.0%
INCY
+11.7%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
B
Bristol-Myers Squibb
BMY
74.4%
+35.0%
I
Incyte
INCY
14.6%
+11.7%
L
Legend Biotech
LEGN
2.3%
−43.9%
E
Enliven Therapeutics
ELVN
2.2%
+140.4%
S
SELLAS Life Sciences
SLS
1.0%
+427.5%
N
Nurix Therapeutics
NRIX
1.0%
+27.2%
D
Damora Therapeutics
DMRA
0.9%
−8.5%
C
Corvus Pharmaceuticals
CRVS
0.6%
+30.1%
S
Syndax Pharmaceuticals
SNDX
0.5%
−43.7%
R
Rigel Pharmaceuticals
RIGL
0.5%
+11.3%
C
Cullinan Therapeutics
CGEM
0.4%
+23.1%
K
Kura Oncology
KURA
0.4%
−27.2%
G
Geron
GERN
0.4%
−22.0%
B
BlossomHill Therapeutics
BLSM
0.3%
C
C4 Therapeutics
CCCC
0.2%
+11.3%
A
Allogene Therapeutics
ALLO
0.2%
−31.8%
A
Ascentage Pharma Group International
AAPG
−55.6%
A
ADC Therapeutics
ADCT
−66.9%
A
Autolus Therapeutics
AUTL
−14.0%
G
Genmab
GMAB
+68.6%
O
BeOne Medicines
ONC
+10.4%